XM on a drug test result stands for xylazine metabolite, meaning the test detected evidence of exposure to xylazine, a veterinary sedative that has become a widespread adulterant in the illicit drug supply. The result does not necessarily mean someone knowingly took xylazine; it more commonly appears because xylazine was mixed into another substance, most often fentanyl. Because xylazine creates health risks that standard overdose treatments do not fully address, laboratories have rapidly added XM panels to their testing menus over the past few years, and the designation is now appearing on results that many patients and clinicians are seeing for the first time.
Why Xylazine Is Showing Up on Drug Tests
Xylazine was developed decades ago as a sedative and anesthetic for animals like horses and cattle. It works by activating a specific class of receptors in the nervous system that slow heart rate, lower blood pressure, and produce deep sedation.1PubMed. Immunomodulatory effect of xylazine, an alpha(2) adrenergic agonist, on rat spleen cells in culture It was never approved for human use. Yet since around 2016, it has consistently appeared as an additive in illegally manufactured fentanyl, likely because it is cheap, easy to obtain, and extends the sedative effect that users associate with the high.2PubMed. Xylazine Adulteration of the Heroin-Fentanyl Drug Supply: A Narrative Review The presence of fentanyl in a fatal overdose has been found to be a strong predictor that xylazine will also be present.3PubMed. Xylazine in the drug supply: Emerging threats and lessons learned in areas with high levels of adulteration
Most people who test positive for xylazine had no idea it was in what they consumed. This is part of why testing for it has become urgent: you cannot manage a health risk you do not know about. An XM result flags that exposure and opens the door to clinical decisions that would not otherwise be on the table.
What the Test Actually Detects
When your body processes xylazine, it breaks the drug down into several metabolites. The one most commonly targeted by screening tests is 4-hydroxy-xylazine, often abbreviated 4-OH-xylazine. A rapid dipstick test developed for clinical urine screening can detect xylazine and its 4-OH metabolite at concentrations as low as 10 nanograms per milliliter, with the metabolite showing full cross-reactivity, meaning the test picks it up just as readily as the parent drug.4PubMed Central. Development and Validation of a High Sensitivity Rapid Xylazine Dipstick for Clinical Urine Testing
Research has identified additional breakdown products in urine, including oxo-xylazine and sulfone-xylazine. In a study of over a hundred patients who tested positive for both fentanyl and xylazine, sulfone-xylazine signal actually exceeded that of xylazine itself in more than 70% of urine samples.5PubMed. Xylazine and major urinary metabolites detected in patients positive for fentanyl and xylazine That finding matters because it suggests future tests might get better sensitivity by targeting sulfone-xylazine instead of, or alongside, the parent drug. For now, though, the XM designation on your result usually reflects detection of xylazine and/or 4-OH-xylazine.
Screening Versus Confirmatory Results
Drug testing for xylazine follows the same two-step logic used for most substances. The first step is a rapid screening test, usually an immunoassay, which gives a quick positive or negative answer. If you see XM on an initial screen, it means the immunoassay flagged likely xylazine exposure. These screening tests are fast but imperfect.
Confirmatory testing uses a more precise technique, typically liquid chromatography paired with tandem mass spectrometry. One validated clinical method detects xylazine down to 1 nanogram per milliliter, alongside fentanyl and norfentanyl.6Journal of Analytical Toxicology. Xylazine and major urinary metabolites detected in patients positive for fentanyl and xylazine – Section: Materials and methods Another method covers a panel of over a hundred toxicologically relevant compounds with xylazine and 4-OH-xylazine added.7Waters Application Notes. Direct-to-Definitive Urine Drug Testing Panel with Addition of Xylazine and 4-Hydroxy Xylazine Identification and Quantitation If your XM result came from a confirmation test, it is highly reliable. If it came only from a rapid screen, the next section matters.
When an XM Result Could Be Wrong
Immunoassay-based xylazine screens have a real cross-reactivity problem. Studies have found that several common drugs and cutting agents can trigger false-positive results, including lidocaine, levamisole, ketamine, methamphetamine, diphenhydramine, promethazine, and cetirizine.8The Journal of Applied Laboratory Medicine. Evaluating the Sensitivity, Selectivity, and Cross-Reactivity of Lateral Flow Immunoassay Xylazine Test Strips These false positives are concentration-dependent, meaning the interference gets worse when the cross-reacting substance is present in larger amounts.
Different brands of test strips vary in how selective they are. Some show cross-reactivity with only one interfering compound, while others react to several.8The Journal of Applied Laboratory Medicine. Evaluating the Sensitivity, Selectivity, and Cross-Reactivity of Lateral Flow Immunoassay Xylazine Test Strips One clinical dipstick showed no cross-reactivity with common drugs or endogenous metabolites except for a 3% cross-reactivity with clonidine, a blood-pressure medication that shares a similar chemical structure.4PubMed Central. Development and Validation of a High Sensitivity Rapid Xylazine Dipstick for Clinical Urine Testing So if you are taking clonidine and get a positive XM screen, that is worth flagging to your clinician before assuming genuine xylazine exposure.
The practical takeaway: a positive immunoassay screen should be confirmed by mass spectrometry before anyone makes major clinical or legal decisions based on it. A negative screen, on the other hand, tends to be more trustworthy, since the false-negative rate is generally the bigger concern in harm-reduction settings.
How Long Xylazine Stays Detectable
Xylazine itself clears from plasma relatively quickly. In a pharmacokinetic study of patients who tested positive for both fentanyl and xylazine, researchers estimated the elimination half-lives of two key metabolites in plasma: roughly 22 hours for oxo-xylazine and about 16 hours for sulfone-xylazine.9Clinical Chemistry. Xylazine Pharmacokinetics in Patients Testing Positive for Fentanyl and Xylazine Metabolite concentrations tracked proportionally with xylazine concentrations rather than accumulating, suggesting the metabolites do not linger dramatically longer than the parent drug in blood.
Urine detection may last somewhat longer because metabolites concentrate there. Sulfone-xylazine, which exceeded parent-drug signal in most urine specimens tested, is not broken down further by a common metabolic pathway called glucuronidation, which could make it a stable urinary marker.5PubMed. Xylazine and major urinary metabolites detected in patients positive for fentanyl and xylazine Research into whether targeting these additional metabolites could extend the detection window is still ongoing. For the moment, you can broadly expect xylazine to be detectable in urine for a few days after exposure, though individual variation in metabolism, dose, and frequency of use will shift that window.
Why Clinicians Care About an XM-Positive Result
Xylazine is not just a curiosity on a lab report. It changes the clinical picture in several concrete ways.
In acute overdose, xylazine adds its own layer of danger on top of whatever opioid it was mixed with. Common symptoms include low blood pressure, slowed heart rate, drowsiness, and lethargy, with more severe cases involving breathing failure.10PubMed. Xylazine poisoning: a systematic review Emergency department data confirm that a slow heart rate on arrival is associated with roughly double the odds that xylazine is on board in someone presenting with an opioid overdose.11PubMed Central. Clinical factors linked to xylazine exposure in emergency department patients with illicit opioid overdose
With chronic exposure, xylazine has been linked to severe skin ulcers and tissue death. The mechanism appears to involve constriction of blood vessels near the skin, cutting off blood flow and impairing the body’s ability to heal wounds. Prolonged use worsens this cycle and raises infection risk.12PubMed Central. Xylazine-Induced Skin Ulcers in a Person Who Injects Drugs in Philadelphia, Pennsylvania, USA These wounds can appear even at injection sites distant from where the drug was administered, which initially puzzled clinicians. If you or someone you know has an XM-positive result alongside non-healing wounds, that connection is important to raise with a healthcare provider.
The Naloxone Problem
This is where an XM result has the most immediate life-or-death relevance. Naloxone, the standard rescue medication for opioid overdose, works by blocking opioid receptors. It reverses the breathing suppression caused by fentanyl or heroin. But xylazine does not act on opioid receptors. It works through a completely different pathway, so naloxone has no direct effect on xylazine-related respiratory depression.
In animal studies, a dose of naloxone sufficient to reverse fentanyl-induced breathing suppression was ineffective against the respiratory effects of fentanyl adulterated with xylazine.13Psychopharmacology. Xylazine exacerbates fentanyl-induced respiratory depression and prevents rescue by naloxone in mice A separate rat study confirmed that naloxone alone only partially decreased the oxygen deprivation caused by a fentanyl-xylazine combination. When researchers added atipamezole, a drug that blocks the same receptor type xylazine activates, the combination of naloxone plus atipamezole was substantially more effective than naloxone alone at reversing the breathing effects.14PubMed Central. Combined treatment with naloxone and the alpha2 adrenoceptor antagonist atipamezole reversed brain hypoxia induced by a fentanyl-xylazine mixture in a rat model
Atipamezole is currently used in veterinary medicine to reverse xylazine sedation in animals. It is not yet approved for human use, but the animal data have generated serious interest in developing it as a companion to naloxone. In the meantime, naloxone should still be administered during a suspected overdose because fentanyl is almost always present alongside xylazine, and reversing the opioid component is still life-saving. Knowing that xylazine is involved, though, helps explain why some overdose patients respond sluggishly to naloxone and may need longer supportive care, including assisted breathing.
Xylazine Withdrawal and Treatment
An XM-positive result also raises the question of withdrawal. Xylazine withdrawal is distinct from opioid withdrawal and can include severe agitation and autonomic instability. There is no established protocol yet, but a published case report describes managing a patient’s xylazine withdrawal with a combination of dexmedetomidine infusion, phenobarbital, and tizanidine, later transitioning to clonidine. The patient’s withdrawal symptoms resolved by the fourth day.15PubMed. Management of Xylazine Withdrawal in a Hospitalized Patient: A Case Report All of those medications share the property of calming the same branch of the nervous system that xylazine acts on, which makes pharmacological sense even if the evidence base is still thin.
For clinicians, this means that a patient with an XM-positive result who is being treated for opioid use disorder may need additional support for xylazine-specific withdrawal symptoms. Standard opioid withdrawal protocols involving buprenorphine or methadone address the opioid component but do not cover the xylazine piece.
Xylazine Test Strips in Harm Reduction Settings
Outside the clinical lab, harm reduction organizations have started distributing xylazine test strips so that people who use drugs can check their supply before consuming it. The performance of these strips has been a mixed bag. In one real-world evaluation from Los Angeles, test strips correctly identified xylazine in only about 54% of confirmed-positive samples. Specificity was better at 87%, but most false positives occurred in samples containing lidocaine.16Harm Reduction Journal. Assessing the real-world performance of xylazine test strips for community-based drug checking in Los Angeles
A separate pilot study found even lower sensitivity: test strips correctly identified xylazine in only about 22% of positive samples. When xylazine was a major component rather than a trace contaminant, agreement rose to 100%, but most real-world samples contain xylazine at low concentrations.17Drug and Alcohol Dependence Reports. Pilot findings on the real-world performance of xylazine test strips for drug residue testing and the importance of secondary testing methods The core issue is that xylazine often makes up less than 1% of a sample by weight, which falls below many strips’ detection threshold.
Test strips remain a useful harm-reduction tool, but they work best as one layer in a broader checking strategy rather than a definitive answer. A negative strip result does not guarantee a sample is xylazine-free, especially at the low concentrations commonly found in the street supply. Confirmatory testing by mass spectrometry remains the only truly reliable method.
The Evolving Legal Landscape Around Xylazine
Xylazine occupies an unusual legal gray area. It is not a federally scheduled controlled substance in the United States, which means its legal status varies dramatically by state. As of recent tallies, nine states have formally scheduled xylazine as a controlled substance, and five additional states have enacted laws imposing criminal penalties for non-veterinary possession or distribution while preserving exemptions for legitimate animal use.18medRxiv. State Xylazine Scheduling and Changes in Xylazine and Medetomidine Reports in the U.S. Illicit Drug Supply: A Quasi-Experimental Study Among proposed state laws, Schedule III has been the most frequently suggested classification level.19PubMed. A content analysis of legal policy responses to xylazine in the illicit drug supply in the United States
This patchwork matters for anyone with an XM-positive result because the legal implications of xylazine detection differ depending on where you live. In states that have scheduled it, a confirmed positive could carry legal weight similar to testing positive for other controlled substances. In states where xylazine remains unscheduled, the finding is clinically significant but does not carry the same legal consequences. The federal government designated xylazine as an “emerging threat” in 2023, which increased funding for research and surveillance but stopped short of formal scheduling.
What to Do if You See XM on Your Results
If you receive a drug test result with an XM designation, a few practical points are worth keeping in mind. First, ask whether the result is from a screening test or a confirmation test. If it is a screen only, cross-reactivity from substances like lidocaine, clonidine, or diphenhydramine could explain the result, and confirmatory testing should be requested before drawing conclusions. Second, if the result is confirmed positive, it most likely indicates that xylazine was mixed into another substance you were exposed to, not that you sought out xylazine specifically. Third, a confirmed positive is clinically meaningful. It may affect how an overdose is managed, what withdrawal symptoms to expect, and whether wound care needs to be evaluated.
For clinicians interpreting these results, the ARK Diagnostics immunoassay, one of the commercially available screening platforms, shows a curvilinear response to both xylazine and 4-OH-xylazine, with highly variable readings at high concentrations above 1,200 nanograms per milliliter.20Journal of Analytical Toxicology. Evaluation of the ARK Diagnostics immunoassay for qualitative detection of xylazine in urine This means a very high screening result should be interpreted qualitatively as positive rather than taken as a reliable quantitative measurement. Precise quantitation requires confirmatory mass spectrometry.
Xylazine testing is still a rapidly developing field. New metabolite targets like sulfone-xylazine may improve sensitivity in the near future, better point-of-care strips are being engineered, and human trials of reversal agents are being discussed. An XM result today captures a snapshot of what labs can currently detect, and the tools will only get sharper from here.